Literature DB >> 17046682

Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.

Jonathan W Yewdell1.   

Abstract

Antiviral CD8(+) T cells respond to only a minute fraction of the potential peptide determinants encoded by viral genomes. Immunogenic determinants can be ordered into highly reproducible hierarchies based on the magnitude of cognate CD8(+) T cell responses. Until recently, this phenomenon, termed immunodominance, was largely defined and characterized in model systems utilizing a few strains of inbred mice infected with a handful of viruses with limited coding capacity. Here, I review work that has extended immunodominance studies to viruses of greater complexity and to the real world of human antiviral immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046682     DOI: 10.1016/j.immuni.2006.09.005

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  188 in total

Review 1.  CD8+ T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation.

Authors:  Anthony J St Leger; Robert L Hendricks
Journal:  J Neurovirol       Date:  2011-12-08       Impact factor: 2.643

2.  CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

Authors:  Charles S Rosenberg; Dianya L Martin; Rick L Tarleton
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

3.  Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Authors:  Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  Expert Rev Vaccines       Date:  2012-01       Impact factor: 5.217

4.  MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA.

Authors:  Brian P Dolan; Aditi A Sharma; James S Gibbs; Tshaka J Cunningham; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

5.  Promiscuous binding of extracellular peptides to cell surface class I MHC protein.

Authors:  Herman N Eisen; Xun Helen Hou; Chase Shen; Kaidi Wang; Varsha Keelara Tanguturi; Crysela Smith; Katerina Kozyrytska; Lakshmi Nambiar; Carol A McKinley; Jianzhu Chen; Richard J Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-07       Impact factor: 11.205

6.  CD8+ T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of toll-like receptor agonists.

Authors:  Sarah Siddiqui; Sameh Basta
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

7.  Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins.

Authors:  Tomer Hertz; David Nolan; Ian James; Mina John; Silvana Gaudieri; Elizabeth Phillips; Jim C Huang; Gonzalo Riadi; Simon Mallal; Nebojsa Jojic
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

8.  Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Authors:  Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 9.  From optical bench to cageside: intravital microscopy on the long road to rational vaccine design.

Authors:  Heather D Hickman; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.